HR-8981-119
Ordered to be Reported in the Nature of a Substitute (Amended) by Voice Vote.
Sponsored by April McClain Delaney (D-MD)
What it does
This bill would create a "biometrology laboratory program" within the National Institute of Standards and Technology (NIST) to research measurement standards, tools, and best practices for engineering biology, biomanufacturing, and biotechnology. It authorizes NIST to fund research, build shared lab facilities ("foundries"), coordinate with other federal agencies and industry, and develop common terminology, with appropriations authorized from $55 million in FY2026 rising to $85 million in FY2030.
Who benefits
Biotechnology and biomanufacturing companies that would gain access to standardized measurement tools, shared testing facilities, and clearer regulatory terminology, reducing their research and compliance costs. Universities and nonprofit research institutions that could use NIST facilities and receive extramural research funding. Federal agencies coordinating biosecurity and biosafety standards, and graduate students and researchers who would benefit from new training programs.
Who is hurt
Taxpayers who would fund the $55-85 million annual appropriations. Smaller biotech firms or academic labs that lack resources to engage with NIST consortia may see relatively less benefit than larger, well-resourced companies and universities already positioned to participate. Competing measurement-science priorities within NIST's budget could see reduced funding as resources shift toward this new program.
Supporters argue
Supporters argue that the United States lacks standardized measurement tools for biomanufacturing, which slows commercialization and puts the country at a competitive disadvantage against nations like China that have made national investments in synthetic biology infrastructure. They contend that establishing common technical standards, shared facilities, and terminology would reduce duplication of effort, improve interoperability across labs and companies, and strengthen both economic competitiveness and biosecurity oversight.
Opponents argue
Opponents argue that the program duplicates existing efforts, such as the National Engineering Biology Research and Development Initiative, and creates additional bureaucratic coordination requirements without clear evidence that NIST is the right agency to lead biological standard-setting. They contend that the escalating five-year authorization commits significant federal funding to a new program with broad, loosely defined activities before demonstrating measurable results from a pilot or smaller-scale effort.